Ligand Pharmaceuticals Incorporated
LGNDNASDAQHealthcare● Active
$237.75
+$0.75(+0.32%)
Market Cap$4.8B
P/E Ratio—
52W High$247.38
52W Low$102.5
Ligand Pharmaceuticals Incorporated (LGND) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LGND · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.27B | $0.17B | $0.13B | $0.20B | $0.24B |
| Cost of Revenue | $0.01B | $0.01B | $0.04B | $0.05B | $0.06B |
| Gross Profit | $0.26B | $0.16B | $0.10B | $0.14B | $0.18B |
| Gross Margin %(computed) | 97.54% | 93.37% | 73.31% | 73.08% | 74.26% |
| Operating Expenses | |||||
| R&D Expenses | $0.08B | $0.02B | $0.02B | $0.04B | $0.03B |
| G&A Expenses | $0.09B | $0.08B | $0.05B | $0.07B | $0.05B |
| Total Operating Expenses | $0.21B | $0.18B | $0.08B | $0.14B | $0.08B |
| Operating Income | $0.05B | ($0.02B) | $0.01B | $0.00B | $0.10B |
| Operating Margin %(computed) | 17.61% | -13.53% | 9.09% | 1.55% | 42.99% |
| Interest Income | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.02B |
| Income Before Tax | $0.16B | $0.00B | $0.06B | $0.04B | $0.07B |
| Income Tax Expense | $0.03B | $0.01B | $0.01B | $0.04B | ($0.00B) |
| Net Income | $0.12B | ($0.00B) | $0.05B | ($0.03B) | $0.06B |
| Net Margin %(computed) | 46.42% | -2.41% | 39.72% | -17.00% | 23.66% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $6.44 | $-0.22 | $3.02 | $-1.98 | $3.46 |
| Wtd Avg Shares | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B |
| EBITDA | $0.19B | $0.04B | $0.10B | $0.08B | $0.14B |
| EBITDA Margin %(computed) | 71.89% | 24.41% | 76.79% | 41.38% | 59.11% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Ligand Pharmaceuticals Incorporated data
About Ligand Pharmaceuticals Incorporated (LGND) Income Statement
Ligand Pharmaceuticals Incorporated (LGND) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, LGND reported revenue of $0.27B, gross profit of $0.26B (gross margin 97.54%), and net income of $0.12B — a net profit margin of 46.42%.
Frequently asked questions
LGND · 4 questionsLigand Pharmaceuticals Incorporated (LGND) reported revenue of $0.27B for 2025, up 60.4% year-over-year.
LGND revenueLGND salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08